Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: May 9, 2024
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025
Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track
Read more at globenewswire.comNYSEARCA:MTNB (7/28/2025, 8:04:00 PM)
0.93
0 (-0.01%)
Find more stocks in the Stock Screener
